Haemophilia

Article	Citations
The detrimental effects of iron to the joint; aggravation by inflammation	84
AHP Oral Abstracts	52
	51
CCS_Book of abstracts	42
Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable	39
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies	32
Into a brave new world: Haemophilia A & von Willebrand Disease Surgery with novel therapies	32
Intracranial haemorrhage among a population of haemophilic patients in Nepal: Challenges and future direction	30
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States	26
A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?	25
The importance and evolution of bleeding disorder registries	25
Haemophilia B, severe childhood obesity and other extra‐haematological features associated with similar 4Mb‐deletions on Xq27: Clinical findings, molecular insights and literature update	25
The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody	24
Direct transfer of data of people with haemophilia from the Thai Haemophilia Treatment Centre Registry to the World Bleeding Disorders Registry of the World Federation of Hemophilia	23
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset	23
Demographics, clinical profile and treatment landscape of patients with haemophilia B in China	23
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review	23
Total joint arthroplasty in the patients with haemophilia: General or neuraxial anaesthesia?	22
The legacy of haemophilia: Memories and reflections from three survivors	21
Is it time for patient involvement in Haemophilia?	21
Health‐related quality of life among adults with haemophilia in China: A comparison with age‐matched general population	20
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view	20
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	20
Issue Information	19
The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033	19

Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	19
Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial	19
Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement	18
PUBLICATION ONLY ABSTRACTS	18
Health technology assessment for gene therapies in haemophilia	17
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	17
Profiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’	16
Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre	16
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective	16
Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries	16
The UK Infected Blood Inquiry: A Personal Reflection	16
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study	16
Initial von Willebrand factor antigen values in adolescent females predict future values	15
Knowledge gaps in health‐related quality of life research performed in children with bleeding disorders – A scoping review	15
Reply to: Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?	15
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy	15
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature	14
Towards achieving a haemophilia‐free mind	14
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	14
Wearable activity trackers in young people with haemophilia: What needs to be considered?	14
Development of the World Federation of Hemophilia Shared Decision‐Making Tool	14
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)	14
Reinvestigation of unidentified causative variants in FXI‐deficient patients: Focus on gene segment deletions	14
Low‐dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success	14
	14
Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency	14
Clinical outcomes of low‐dose pharmacokinetic‐guided extended half‐life versus low‐dose standard half‐life factor VIII concentrate prophylaxis in haemophilia A patients	14
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters	14
Haemophilic arthropathy: Contemporary management challenges and a future scenario	13
Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project	13
Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A	13
Occurrence of familial Mediterranean fever in haemophilia patients	13
A survey on practice of circumcision in children with severe haemophilia in Eastern Mediterranean Region	13
Impact of first COVID‐19 lockdown on paediatric and adult haemophilia patients treated in a French Haemophilia Comprehensive Care Centre	13
AUTHOR INDEX	13
Complete characterisation of two new large Xq28 duplications involving F8 using whole genome sequencing in patients without haemophilia A	13
Anti‐platelet treatment challenges in Glanzmann thrombasthenia‐clinical practice when data lacks	13
AUTHOR INDEX	12
Assessment of rare bleeding disorders in adolescents with heavy menstrual bleeding	12
Emicizumab and asparaginase, A first experience to share	12
A 10‐year single‐institution retrospective review of treatment for acquired hemophilia A	12
von Willebrand disease and von Willebrand factor	12
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy	12
Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review	12
Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes	12
Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms	12
A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials	12
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real‐Life Case Series and Literature Review	12
Factor XIII levels correlate with fibrinogen concentrations in patients with venous malformations	12
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	12

Development of a target product profile (TPP) for haemophilia point‐of‐care (POC) diagnostic devices for low‐resource countries and remote settings	12
The lived experience of mothers of children with haemophilia in Jordan: A phenomenological study	12
Pharmacokinetic profile of children with haemophilia A receiving low‐dose FVIII prophylaxis in Indonesia: A single centre experience	12
Factors associated with physical activity in young people with haemophilia A on prophylaxis	12
	11
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients	11
The state of oral health in patients with haemophilia in the Netherlands	11
Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients	11
Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease	11
Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies	11
Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis	11
Systematic Literature Review of Outcomes Associated With Adherence to Haemophilia Drug Therapy	11
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review	11
Physical Activity Awareness and Understanding of Treatment Protection Among People With Haemophilia and Their Caregivers in Central Europe	11
Determining causes of death among individuals with haemophilia in Afghanistan	10
Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers	10
Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time	10
Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A	10
Management of Persons With Haemophilia Requiring Antithrombotic Therapy: A Canadian Modified Delphi Consensus Study	10
Performance on the iSTEP and 10 m‐ISWT in boys with haemophilia	10
Book of Abstracts	10
Ankle joint distraction is a promising alternative treatment for patients with severe haemophilic ankle arthropathy	10
Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen	10
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity	10
Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study	10
Haemophilia Carriers Experience Study (CARES): A mixed method exploration into the experience of women who are carriers of Haemophilia	10
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience	10
The haemophilia joint health score for the assessment of joint health in patients with haemophilia	10
Haemophilia diagnostics with modern genomics	9
Democratisation of physiotherapy for people with haemophilia	9
Author Index	9
Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers	9
HRQoL and psychosocial aspects of burden on caregivers to children with moderate or severe von Willebrand disease	9
Patient‐centred research agenda for females with bleeding disorders	9
Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis	9
Real‐World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study	9
Clotting factor activity levels and bleeding risk in people with haemophilia playing sports	9
Clinical characteristics and prognostic factors of acquired haemophilia A in Korea	9
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine	9
Immune checkpoint inhibitor‐induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system	9
The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: An integrative review	9
Molecular study of a large cohort of 109 haemophilia patients from Cuba using a gene panel with next generation sequencing‐based technology	9
Retraction	9
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature	9
Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome	9
The relationship between chronic pain and psychosocial aspects in patients with haemophilic arthropathy. A cross‐sectional study	9
Does the method of telehealth delivery affect the physiotherapy management of adults with bleeding disorders? A comparison of audioconferencing and videoconferencing	9
Validity and reliability test of the Indonesian version of the PedHALshort questionnaire	9
	8
European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients	8
POSTER PRESENTATIONS	8
Harmonizing patient‐reported outcome measurements in inherited bleeding disorders with PROMIS	8
Identifying performance‐based outcome measures of physical function in people with haemophilia (IPOP)	8
	8
Endothelial specific isoform of type XVIII collagen (COL‐18N): A marker of vascular integrity in haemophilic arthropathy	8
Comparison of free‐living physical activity measurements between ActiGraph GT3X‐BT and Fitbit Charge 3 in young people with haemophilia	8
Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH)	8
Is the world ready for gene therapy?	8
Comprehensive Analysis of Surgical Interventions for Musculoskeletal Disorders in Patients With Bleeding Disorders: Report From a Subspecialty Unit in a Developing Country	8
Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States	8
Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency—A large single‐centre experience	8
Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal	8
COMMITTEE LIST	8
Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study	8
Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?	8
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B	8
Gene therapy: Practical aspects of implementation	8
European principles of care for women and girls with inherited bleeding disorders	8
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	8
Clinical, biological, and genetic features in an afibrinogenemia patient series in Algeria	7
Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan	7
Hemizygous FGG p.Ala108Gly in a hypofibrinogenemic patient with a heterozygous 14.8 Mb deletion encompassing the entire fibrinogen gene cluster	7
Experiences and Needs Regarding Information Provision in Children With Haemophilia: A Qualitative Study on Caregivers’ and Healthcare Providers’ Perspectives	7
Issue Information	7
Clinical and Economic Burden of Patients with Haemophilia A and B in France: Analysis of a Nationwide Claims Database	7
	7
Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay	7
Bone marrow oedema syndrome as a cause of chronic knee pain in a person with severe Haemophilia A	7
Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐ce	7
Treatment of haematuria with factor concentrate in people with haemophilia is associated with low rates of complications	7

Five new F10 variants in hereditary factor x deficiency detected by high‐throughput sequencing	7
	7
Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study	7
Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study	7
Issue Information	7
Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2)	7
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B	7
Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience	7
Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees	7
Haemophilia care in Asia: Learning from clinical practice in some Asian countries	7
Abstracts	7
Committee List	7
Preoperative bleeding risk assessment with ISTH‐BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study	7
Psychophysical assessment of pain in adults with moderate and severe haemophilia: A cross‐sectional study	6
Diagnosis of rare bleeding disorders	6
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders	6
Efficacy and Safety of Aspiration and Intra‐Articular Injection of Tranexamic Acid in Acute Knee Hemarthrosis of Adult Haemophilic Patients: A Randomized Clinical Trial Study	6
Diagnosis and treatment of von Willebrand disease in 2024 and beyond	6
Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database	6
Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study	6
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy	6
Deciphering a novel complex inversion affecting F8 in a family with severe haemophilia A by optical genome mapping	6
Dental habits and oral health in children and adolescents with bleeding disorders: A single‐institution cross‐sectional study	6
Low immunogenicity of emicizumab in persons with haemophilia A	6
A distinct common p.Gln317* mutation among causative LMAN1 genetic mutations of combined factor V and factor VIII deficiency in five Taiwanese families	6
Research Letter: Patient Attitudes Towards Haemophilia Gene Therapy at a US Haemophilia Treatment Center	6
	6
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes	6
Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences	6
Clinical features and genetic defect in six index patients with congenital fibrinogen disorders: Three novel mutations with one common mutation in Taiwan's population	6
A systematic review and narrative synthesis of footwear and orthotic devices used in the management of ankle haemarthrosis and haemarthropathy in haemophilia	6
A national assessment of standards of care for inherited bleeding disorders in Canada	6
POSTER ABSTRACTS	6
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group	6
Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause	6
Molecular spectrum of inherited FVII deficiency in North India revealed a recurrent variant with a founder effect	5
EAHAD statement on the ISTH clinical practice guideline for treatment of congenital haemophilia A and B	5
The effect of carriers’ reproductive choices and pregnancy history on sporadic severe haemophilia: A 20‐year retrospective study through a regional registry	5
Issue Information	5
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A	5
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	5
Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab	5
What can we expect for adolescents and adults with haemophilia switched to low‐dose prophylaxis from episodic treatment for over 3 years? A real‐world snapshot in China	5
Nephrotic syndrome in two haemophilia B children with inhibitor under low‐dose immune tolerance induction combined with rituximab‐based immunosuppressant protocol	5
Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding	5
Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series	5
Invited Medical Presentation Abstracts	5
Depression and anxiety in persons with Von Willebrand disease	5
Real‐world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea	5
The effect of a virtual child disease management programme on burden and social adjustment of caregivers of children with coagulation factor deficiencies	5
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey	5
Vaccination in children with inherited bleeding disorders: Does the use of plasma an d factor affect the response to the vaccine: An institutional registry	5
UK haemophilia consultant access to foot and ankle services and concurrent patient impact questionnaire responses to foot and ankle interventions	5
Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States	5
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry	5
Defining success in haemophilia care – Are we doing it right?	5
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	5
Effects of a supervised therapeutic exercise program on musculoskeletal health and gait in patients with haemophilia: A pilot study	5
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy	5
Prophylaxis in children with haemophilia in an evolving treatment landscape	5
Women and girls’ participation in haemophilia clinical trials	5
Acquired bleeding disorders	5
Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe	5
Psychological and cognitive factors involved in decision‐making process of haemophilia carriers in reproductive choices	5
Differences and similarities in patient‐reported outcomes among men and women with haemophilia	5
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK	5
	5
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 1	5
Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience	5
Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China	5
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B	5
Association of factor expression levels with annual bleeding rate in people with haemophilia B	5
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot®) and emicizumab in patients with haemophilia A and inhibitors and	5
Issue Information	5
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD	5